New combo therapy tested for Tough-to-Treat colon cancer
NCT ID NCT03828799
Summary
This study tested the safety and effectiveness of combining two cancer drug regimens—regorafenib and FOLFIRINOX—for patients with advanced colorectal cancer that has spread and has a specific RAS gene mutation. The main goal was to find the highest dose patients could tolerate without severe side effects. It was a small, early-phase trial involving 13 participants to see if this combination could help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, Alpes-Maritimes, 06189, France
-
Centre Cario - HPCA
Plérin, Finistère, 22190, France
-
Centre Georges-François Leclerc
Dijon, Côte d'Or, 21079, France
-
Institut du Cancer de Montpellier - Val d'Aurelle
Montpellier, 34298, France
Conditions
Explore the condition pages connected to this study.